Please login to the form below

Not currently logged in
Email:
Password:

alirocumab

This page shows the latest alirocumab news and features for those working in and with pharma, biotech and healthcare.

Dupixent helps put Sanofi back on growth track

Dupixent helps put Sanofi back on growth track

Meanwhile, cholesterol-lowerer Praluent (alirocumab) sales came in at 68m in the quarter – up 64% year-on-year but still way below initial expectations, largely as a result of a reluctance

Latest news

More from news
Approximately 10 fully matching, plus 57 partially matching documents found.

Latest Intelligence

  • Pharma deals in May 2015 Pharma deals in May 2015

    Sanofi has been adept in this area with its previous access to a PRV for Alirocumab for dyslipidaemia (in partnership with Regeneron who had originally purchased the PRV from Biomarin) for

  • Going the distance Going the distance

    Looking to the second half of this year and Sanofi is aiming for a Q3 launch for its new PCSK9 cardiovascular disease management drug Praluent (alirocumab), which comes from its collaboration

  • Pharma deals during November 2014 Pharma deals during November 2014

    In July, BioMarin sold its PRV to Regeneron for $68m to expedite filing of its cholesterol drug, the PCSK9 inhibitor alirocumab, being developed in partnership with Sanofi.

More from intelligence
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
infill healthcare communication

infill is a dynamic and innovative, international healthcare agency with >25 years' experience in delivering healthcare communication, medical education and...

Latest intelligence

NHS regional footprints
What to expect from 2019...
Not another weight-loss ad
Christmas is over and the gyms are packed, it’s a never-ending tale. But why do we do it to ourselves every year?...
China’s clinical trial shake-up
As many of the obstacles to running clinical trials in China fall away, the country is proving to be a better research location...

Infographics